Dry age-related macular degeneration (AMD) is a medical condition that primarily affects the central part of the retina, known as the macula, leading to progressive loss of central vision. Within the optics industry, the market for dry AMD encompasses various aspects such as diagnosis, monitoring, and management of the condition, although there are currently limited treatment options directly targeting the underlying pathology. The market includes specialized optical devices for diagnosis such as fundus cameras, optical coherence tomography (OCT) machines, and visual field analyzers used by ophthalmologists and optometrists. Additionally, it comprises a range of low vision aids designed to help patients cope with vision impairment, including specialized eyewear, magnifying devices, and adaptive technology.
Moreover, ongoing research into potential treatments and therapies for dry AMD continues to be a part of the optical market landscape. Pharmaceutical companies, biotech firms, and research institutions are heavily invested in developing medications, supplements, and innovative therapies to slow the progression of dry AMD or to improve the quality of life for those affected.
Prominent companies operating in the dry age-related macular degeneration market include Novartis, Roche, Regeneron Pharmaceuticals, Bayer, and Bausch + Lomb. These companies are involved in various aspects of the market, from the development of therapies and treatments to the provision of diagnostic equipment and visual aids. Show Less Read more
